Stocks and Investing
Stocks and Investing
Fri, May 6, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $27 on, May 6th, 2022
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $26 to $27 on, May 6th, 2022.
Mani has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mani
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $22 on, Wednesday, March 16th, 2022
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $18 on, Friday, March 11th, 2022
Contributing Sources